77 results on '"Zielinski C"'
Search Results
2. Relationship of 4F2hc expression and grade of malignancy in renal cell cancer (RCC).
3. Vaccination of cancer patients with whole-virion, adjuvant-free pandemic influenza H1N1 vaccine: Patient acceptance and vaccine immunogenicity.
4. Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).
5. Capecitabine (Cap) monotherapy in anthracycline (A)/taxane (T)-pretreated MBC.
6. Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
7. Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC).
8. Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
9. Locally advanced gastric cancer treated with neoadjuvant chemotherapy: Epirubicin, oxaliplatin, and capecitabine (EOX).
10. D-dimer levels and prediction of overall survival in cancer patients.
11. Predictive role of carcinoembryonic antigen (CEA) for therapeutic efficacy of angiogenesis-targeting therapy in colorectal cancer: Novel clinical observation based upon recently discovered CEA biology.
12. Health-related quality of life (HQOL) and early survival outcome of the randomized adjuvant dose-dense (dd) FEC75 versus FEC90 CECOG study.
13. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.
14. Pro-BNP for detection of sunitinib-induced cardiac toxicity in patients with renal cell carcinoma.
15. Neoadjuvant chemotherapy in locally advanced gastric cancer with epirubicin, oxaliplatin, and capecitabine (EOX): A retrospective analysis.
16. Fulvestrant (F) as first-line palliative treatment for hormone receptor (HR)- positive metastatic breast cancer.
17. Treatment with bevazicumab and liposomal doxorubicin for recurrent high-grade gliomas (HGGs).
18. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
19. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
20. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
21. Evaluating the impact of relative total dose intensity (RTDI) on patient's short- and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer: A pooled analysis
22. Phase II study: WBRT ±temozolomide (TMZ) in patients with multiple brain metastases from non-small cell lung cancer (NSCLC)
23. Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX+C) or FOLFIRI + cetuximab (FF+C): The CECOG/CORE1.2.001 trial
24. Predicting response to second-line trastuzumab-based therapy in patients (pts) with HER2-positive advanced breast cancer (ABC)
25. Use of the ErbB2/CEP17 ratio to predict prognosis and response to trastuzumab-based therapy in the metastatic breast cancer setting
26. Time interval between final protocol approval (FPA) and inclusion of the first patient into randomized clinical trials (RCTs) performed by the Central European Cooperative Oncology Group (CECOG): A 10-year experience
27. Severe thrombocytopenia after the first cycle of temozolomide: Who is at risk?
28. Temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma: Preliminary results from the Austrian Compassionate Use Program
29. A phase I study to evaluate safety, immunogenicity and antitumor activity of a HER2 multi-peptide virosome vaccine in patients with metastatic breast cancer
30. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study
31. Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine
32. A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
33. Analysis of risk factors predicting time to development of brain metastases
34. Tolerability of pemetrexed versus placebo as a maintenance therapy in advanced non-small cell lung cancer: Evidence from a large randomized study
35. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05)
36. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death and abrogates invasive growth of melanoma cells
37. Progression-free survival in a phase II study of perioperative bevacizumab plus XELOX in patients with potentially curable metastatic colorectal cancer
38. Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease. Results of the CECOG-Study ESGAS.1.2.001
39. Effectiveness of neoadjuvant chemotherapy including bevacizumab in patients with resectable colorectal cancer liver metastases
40. Cardiac involvement in patients with sorafenib or sunitinib treatment for metastatic renal cell carcinoma
41. Vaccination with a CEA epitope mimic leads to reduced growth of tumor transplants
42. The Hsp32/HO-1-targeted drug SMA-ZnPP counteracts the proliferation and viability of neoplastic cells in solid tumors and hematologic neoplasms
43. Expression and secretion of VEGF in solid tumor cells is mediated by the mammalian target of rapamycin (mTOR)
44. Bevacizumab plus XELOX as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
45. Trastuzumab (T) plus capecitabine (C) in heavily pretreated patients (pts) with advanced breast cancer (ABC)
46. Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma
47. Trastuzumab mimotope vaccination of HER-2/neu transgenic mice results in prolonged tumor-free survival and reduced tumor load
48. Neoadjuvant chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer
49. Delay in time to worsening of symptoms (TWS) of advanced non-small cell lung cancer (NSCLC) using gemcitabine (gem) maintenance therapy
50. Intensified local treatment and systemic therapy significantly increase time to progression and survival in patients with brain metastases from advanced breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.